GLP-1 drugs seem to fight addiction by reducing the hormone dopamine in a brain system involved in reward, motivation and stress a system "that is co-opted or hijacked, if you will, by addiction," Al-Aly says
Retatrutide Weight Loss Results Phase 2 trial data published in 2023 showed that retatrutide at the 12 mg dose produced an average weight loss of approximately 24.2% at 24 weeks , with projections suggesting that the loss could approach 2829% at 48 weeks based on the observed trajectory
Classic anticonvulsants such as pheytoin and carbamazepine had a relatively high EID ( 1:50,000)
In most cases, visible improvements in skin tone and brightness appear within 46 weeks of starting treatment
cant afford the cost of standard doses of the medication
Often, obesity contributes to this problem significantly, as excessive body weight can create increased wear and tear on joints and also lead to metabolic syndrome, thereby slowing the healing process and increasing chronic inflammation